| AAV | adeno-associated virus |
| AMD | age-related macular degeneration |
| AP | alternative pathway |
| ARM | age-related maculopathy |
| BRB | blood-retina barrier |
| C3 | complement component 3 (same for C2, C4, etc.) |
| C3(H2O)Bb | fluid-phase C3-convertase |
| CC | choriocapillaris |
| CNV | choroidal neovascularization |
| CP | classical pathway |
| CR1 | complement receptor 1 |
| dAMD | dry AMD |
| EMA | European Medicines Agency |
| ECM | extracellular matrix |
| FDA | Food and Drug Administration |
| FB | factor B |
| FD | factor D |
| FH | factor H |
| FI | factor I |
| GA | geographic atrophy |
| GAG | glycosaminoglycans |
| GWAS | genome-wide association study |
| Ig | immunoglobulin |
| KO | knock-out |
| LP | lectin pathway |
| MAC | membrane-attack complex |
| MASP | MBL-associated serine protease |
| MBL | mannose-binding lectin |
| mRNA | messenger RNA |
| PEDF | pigment endothelial-derived factor |
| PR | photoreceptor |
| rCD59 | recombinant CD59 |
| RPE | retinal pigment epithelium |
| SNP | single nucleotide polymorphism |
| TNF-α | tumor necrosis factor-alpha |
| VEGF | vascular endothelial growth factor |
| wAMD | wet AMD |